-
European stocks gain as oil prices ease
-
Arteta coy over Lewis-Skelly's Arsenal future after 'emotional' celebration
-
Infantino future should be decided by election says African football chief
-
Romania shuts down nuclear plant as Danube drops
-
Man City star Doku signs five-year contract extension
-
German steel giant Thyssenkrupp weighs options as Rhine drops
-
Fabien Barthez joins Zidane's new France coaching setup
-
US ambassador denounces settler siege as Israel dispatches troops
-
Taiwan chokes mobile internet speeds in drill for Chinese attack
-
Hasan takes 6-55 as Bangladesh claim opening day of Australia Test
-
From Chinese AI to Global ETFs: STARTRADER Launches 45 New 24/7 Stock and ETF CFDs
-
Taiwan says AI agents used in cyberattacks targeting island
-
Tech stocks enjoy rebound after US inflation on mixed day for markets
-
Japan protests Putin's first visit to disputed islands
-
Hasan takes 6-55 as Bangladesh bundle out Australia for 198
-
Kiss wants fit-again Wallabies playmaker Gordon to 'open up' Japan
-
Swiatek sinks Svitolina to set up Rybakina title clash in Toronto
-
British eccentrics push humble garden shed to new heights
-
Australia's Pallister shines, mixed relay record falls as Pan Pacs open
-
Zambia votes with president's economic record on the line
-
Hasan puts Bangladesh in charge as Australia struggle to 183-8
-
Germany's dry rivers spark battle on engineering vs restoration
-
Putin visits Kuril islands claimed by Japan
-
Senators demand inquiry into conditions aboard USS Abraham Lincoln
-
Swiatek downs Svitolina to reach first WTA final of 2026
-
All Blacks' Proctor out of South Africa series, Mo'unga called up
-
Jones says Japan 'watching videos of geese' for Australia clash
-
Bangladesh quick Hasan reduces Australia to 74-4 at lunch
-
Bloodied but unbowed, defending champ Shelton reaches Montreal final
-
Seoul tech leads Asian stock gains as traders cheer US inflation
-
Wallabies make eight changes for return Japan Test
-
Farage and Count Binface go head-to-head in snap UK poll
-
Messi returns after father's death but Miami knocked out of Leagues Cup
-
Afghan students divided over smartphone ban at universities
-
Outflanked by AI, stars fade for South Korea's blind fortune-tellers
-
Japan go back to school for second Australia Test
-
Venezuela govt, opposition wrap up round of post-Maduro talks
-
Matthew McConaughey on his sweet return to the big screen
-
Five things to know about Zambia as it goes to the polls
-
President's economic record on the line as Zambia votes
-
Nakashima holds off Jodar to book first ATP Masters final in Montreal
-
Healthcare Machine Learning Hits Production Scale as Governance Falls Behind, Black Book's Fourth Annual Report Finds
-
iFabric Corp. Announces Record Revenues for Q2 and H1 2026
-
Who Does MTF Body Feminization Surgery?
-
Zomedica Announces Strategic Collaboration with Boehringer Ingelheim Animal Health Canada Inc. to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA(R) Platform
-
Magellan Copper and Gold Corp. Forms New Subsidiary Magellan Energy Corp.
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - August 13
-
3 Home Repairs You Can't Afford to Put Off
-
Battery X Metals Announces Closing of Second Tranche of Private Placement to Advance Corporate Growth Initiatives
-
Battery X Metals Appoints Lithium-Ion Battery and Electric Vehicle Entrepreneur William Fan as President to Advance Development of Its Patent-Pending Lithium-Ion Battery Rebalancing Technology Platform and Corporate Growth Initiatives
US drug regulator limits use of J&J Covid vaccine
The US said Thursday only adults who "have personal concerns" about mRNA vaccines, access issues or medical reasons for refusing them may now receive the Johnson & Johnson Covid shot, which has been linked to a rare but serious clotting condition.
The vaccine, which was authorized as a single shot, is less protective than those developed by Pfizer and Moderna, and in December the Centers for Disease Control and Prevention advised the public to steer clear.
Thursday's decision by the Food and Drug Administration builds on that recommendation by limiting the J&J vaccine's emergency use authorization.
"Today's action demonstrates the robustness of our safety surveillance systems and our commitment to ensuring that science and data guide our decisions," said FDA scientist Peter Marks in a statement.
Sixty US cases of thrombosis with thrombocytopenia syndrome (TTS), which produces rare and potentially life-threatening blood clots with low levels of blood platelets, had been reported by March 18, with nine deaths.
Symptoms begin approximately one to two weeks following administration, and the condition -- which can cause life-long impacts even when not fatal -- occurs more frequently in premenopausal women.
Concerns over the vaccine have already limited uptake: Only 18.7 million doses have been administered in the United States, or about 3.2 percent of the total 577 million.
But the FDA stopped short of an outright de-authorization, with Marks acknowledging the impact a ban might have on global use of the vaccine, as well as concerns some may have specifically against mRNA vaccines, rather than the adenovirus vector platform J&J uses.
There are certain health-based justifications for not taking an mRNA vaccine -- such as rare instances of heart inflammation in adolescent males and young men -- although these are usually transient in nature and the vast majority affected recover completely.
However, anti-vaccine groups have also raised more general objections against mRNA vaccines, which are tied to conspiracy theories.
Although those types of concerns are not rooted in evidence, the exemption to use J&J's shot nonetheless extends to "individuals who have personal concerns with receiving mRNA vaccines and would otherwise not receive a Covid-19 vaccine," the FDA's statement said.
R.Chavez--AT